Immune response to pneumococcal polysaccharide vaccine in adults with chronic plaque psoriasis treated with alefacept

Journal of the American Academy of Dermatology

Volumn 65, Issue 4, 2011, Pages 799-806

  Lynde, Charles ^a   Krell, James ^b   Korman, Neil ^c   Mathes, Barbara ^d  

^a Lynde Centre for Dermatology Canada   (Canada)

^b Total Skin and Beauty Dermatology Center   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

alefacept; biologics; pneumococcal polysaccharide vaccine; psoriasis; T cells; vaccines

Indexed keywords

ALEFACEPT; PNEUMOCOCCUS VACCINE;

ADULT; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; CD4+ T LYMPHOCYTE; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; IMMUNE RESPONSE; MIGRAINE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS VULGARIS; REVIEW; STATISTICAL SIGNIFICANCE;

EID: 80052810558     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2010.04.040     Document Type: Article

References (29)

1. J.G. Krueger The immunologic basis for the treatment of psoriasis with new biologic agents J Am Acad Dermatol 46 2002 1 23 (Pubitemid 34073472)
2. A. Di Cesare, P. Di Meglio, and F.O. Nestle The IL-23/Th17 axis in the immunopathogenesis of psoriasis J Invest Dermatol 129 2009 1339 1350
3. W.H. Boehncke, J. Prinz, and A.B. Gottlieb Biologic therapies for psoriasis: a systematic review J Rheumatol 33 2006 1447 1451 (Pubitemid 44025168)
4. Amevive (alefacept) [prescribing information]. Astellas Pharma US Inc. Deerfield, IL; 2010.
5. +) cells J Immunol 168 2002 4462 4471 (Pubitemid 34441348)
6. + human T cells Eur J Immunol 33 2003 666 675 (Pubitemid 36367670)
7. C.N. Ellis, and G.G. Krueger Alefacept Clinical Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes N Engl J Med 345 2001 248 255 (Pubitemid 32695064)
8. G.G. Krueger, K.A. Papp, D.B. Stough, K.H. Loven, W.P. Gulliver, and C.N. Ellis Alefacept Clinical Study Group. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis J Am Acad Dermatol 47 2002 821 833 (Pubitemid 35403039)
9. M. Lebwohl, E. Christophers, R. Langley, J.P. Ortonne, J. Roberts, and C.E. Griffiths An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis Arch Dermatol 139 2003 719 727 (Pubitemid 36705938)
10. + T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study J Am Acad Dermatol 49 2003 816 825 (Pubitemid 37314868)
11. J.G. Krueger, H.D. Ochs, P. Patel, E. Gilkerson, E. Guttman-Yassky, and W. Dummer Effect of therapeutic integrin (CD11a) blockade with efalizumab on immune responses to model antigens in humans: results of a randomized, single blind study J Invest Dermatol 128 2008 2615 2624
12. M. Lebwohl, J. Bagel, J.M. Gelfand, D. Gladman, K.B. Gordon, and S. Hsu From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis J Am Acad Dermatol 58 2008 94 105 (Pubitemid 350302037)
13. Centers for Disease Control and Prevention Recommended adult immunization schedule-United States, 2009 MMWR Morb Mortal Wkly Rep 57 53 2008
14. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). Available from: URL: http://www.cdc.gov/mmwr/PDF/rr/rr4608.pdf. Accessed August 24, 2009.
15. S. Marmon, and B.E. Strober Balancing immunity and immunosuppression: vaccinating patients receiving treatment with efalizumab J Invest Dermatol 128 2008 2567 2569
16. P.J. Baker Regulation of magnitude of antibody response to bacterial polysaccharide antigens by thymus-derived lymphocytes Infect Immun 58 1990 3465 3468 (Pubitemid 20353339)
17. P.J. Mease, C.T. Ritchlin, R.W. Martin, A.B. Gottlieb, S.W. Baumgartner, and D.J. Burge Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept J Rheumatol 31 2004 1356 1361 (Pubitemid 38879202)
18. M.C. Kapetanovic, T. Saxne, A. Sjöholm, L. Truedsson, G. Jönsson, and P. Geborek Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis Rheumatology (Oxford) 45 2006 106 111 (Pubitemid 43033885)
19. J.L. Kaine, A.J. Kivitz, C. Birbara, and A.Y. Luo Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab J Rheumatol 34 2007 272 279
20. S. Visvanathan, G.F. Keenan, D.G. Baker, A.I. Levinson, and C.L. Wagner Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone J Rheumatol 34 2007 952 957 (Pubitemid 46774837)
21. E.S. Go, and Z.K. Ballas Anti-pneumococcal antibody response in normal subjects: a meta-analysis J Allergy Clin Immunol 98 1996 205 215 (Pubitemid 26289404)
22. N.D. Hare, B.J. Smith, and Z.K. Ballas Antibody response to pneumococcal vaccination as a function of preimmunization titer J Allergy Clin Immunol 123 2009 195 200
23. Pneumovax 23 (pneumococcal vaccine polyvalent) [prescribing information]. Merck & Co Inc. Whitehouse Station, NJ; 2010.
24. World Health Organization. Meeting report: WHO/Health Canada consultation on serological criteria for evaluation and licensing of new pneumococcal vaccines; July 7-8, 2008; Ottawa, Canada. Available from: URL: http://www.who.int/biologicals/publications/meetings/areas/vaccines/ pneumococcal/Pneumo%20Meeting%20Report%20FINAL%20IK%2024-Dec-08.pdf. Accessed August 25, 2009.
25. H.P. Brezinschek, T. Hofstaetter, B.F. Leeb, P. Haindl, and W.B. Graninger Immunization of patients with rheumatoid arthritis with antitumor necrosis factor alpha therapy and methotrexate Curr Opin Rheumatol 20 2008 295 299 (Pubitemid 351483319)
26. Z.Q. Wu, Q. Vos, Y. Shen, A. Lees, S.R. Wilson, and D.E. Briles In vivo polysaccharide-specific IgG isotype responses to intact Streptococcus pneumoniae are T cell dependent and require CD40- and B7-ligand interactions J Immunol 163 1999 659 667 (Pubitemid 29328070)
27. A. Jeurissen, M. Wuyts, A. Kasran, S. Ramdien-Murli, L. Boon, and J.L. Ceuppens Essential role for CD40 ligand interactions in T lymphocyte-mediated modulation of the murine immune response to pneumococcal capsular polysaccharides J Immunol 168 2002 2773 2781 (Pubitemid 34211656)
28. A. Jeurissen, G. Wuyts, A. Kasran, S. Ramdien-Murli, N. Blanckaert, and L. Boon The human antibody response to pneumococcal capsular polysaccharides is dependent on the CD40-CD40 ligand interaction Eur J Immunol 34 2004 850 858 (Pubitemid 39255933)
29. M. Boudewijns, A. Jeurissen, M. Wuyts, L. Moens, L. Boon, and J.J. Van Neerven Blockade of CTLA-4 (CD152) enhances the murine antibody response to pneumococcal capsular polysaccharides J Leukoc Biol 78 2005 1060 1069 (Pubitemid 41572469)